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In this 3-year, open-label, multicenter study, 57 maintenance heart transplant recipients (>1 year after transplant) with renal
insufficiency (eGFR 30–60mL/min/1.73m2) were randomized to start everolimus with CNI withdrawal (𝑁 = 29) or continue their
current CNI-based immunosuppression (𝑁 = 28). The primary endpoint, change in measured glomerular filtration rate (mGFR)
from baseline to year 3, did not differ significantly between both groups (+7.0mL/min in the everolimus group versus +1.9mL/min
in the CNI group, 𝑝 = 0.18). In the on-treatment analysis, the difference did reach statistical significance (+9.4mL/min in the
everolimus group versus +1.9mL/min in the CNI group, 𝑝 = 0.047). The composite safety endpoint of all-cause mortality, major
adverse cardiovascular events, or treated acute rejection was not different between groups. Nonfatal adverse events occurred in
96.6% of patients in the everolimus group and 57.1% in the CNI group (𝑝 < 0.001). Ten patients (34.5%) in the everolimus group
discontinued the study drug during follow-up due to adverse events. The poor adherence to the everolimus therapy might have
masked a potential benefit of CNI withdrawal on renal function.
1. Introduction
Calcineurin inhibitors (CNIs) have made an invaluable
contribution to the improvement of short and mid-term
survival after heart transplantation [1]. However, their use
is associated with significant long-term side effects. CNI
nephrotoxicity is of particular concern. One in ten heart
transplant recipients will ultimately develop end stage renal
failure, which is associated with a more than fourfold
increase in mortality [2, 3]. Furthermore, CNIs contribute
to metabolic disturbances such as posttransplant diabetes
mellitus, dyslipidemia, and hypertension and predispose to
posttransplant malignancies and infection [4, 5]. Finally,
CNIs do not prevent the development cardiac allograft
vasculopathy (CAV) [6].
The availability of everolimus has sparked interest in the
development of CNI-sparing and CNI-free immunosuppres-
sive strategies. Everolimus is a derivative of sirolimus (rapa-
mycin) and works similarly as a mammalian target of rapa-
mycin (mTOR) inhibitor. It does not inhibit interleukin-
2 production from antigen-induced T-cell activation but
inhibits growth-factor induced cellular proliferation in
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response to alloantigens [7], hence the name “proliferation
signal inhibitor.” Several characteristics make everolimus an
attractive alternative for CNIs in heart transplant recipients.
First, everolimus is not nephrotoxic. By reducing exposure to
CNIs, it could potentially preserve renal function [1]. Second,
everolimus restricts growth factor-dependent proliferation of
vascular smoothmuscle cells [8]. It has been shown to signifi-
cantly decrease the incidence of CAV in de novo trials [9–12].
Third, everolimus interferes with the phosphatidylinositol 3-
kinase pathway, a critical step for viral signaling and repli-
cation. There is convincing evidence indicating a reduced
rate of cytomegalovirus (CMV) infection in everolimus-
treated heart transplant recipients [13–15]. Fourth, everolimus
exhibits antiproliferative activity. This has led to its licens-
ing in the treatment of renal cell carcinoma and other
tumors [16]. Although doses prescribed for malignancies are
much higher, preliminary data suggest that everolimus-based
immune suppression could decrease the incidence of certain
post-transplant malignancies [17, 18].
However, the widespread implementation of everolimus
in heart transplantation has been limited by several con-
cerns. First, when combined with CNIs, everolimus seems to
potentiate CNI nephrotoxicity, unless CNI dose is substan-
tially decreased [1, 7, 19, 20]. Second, de novo CNI-free
immunosuppression or early CNI withdrawal is associated
with a higher rejection rate [21, 22]. Third, everolimus is
poorly tolerated, especially at higher doses [19]. It is associ-
ated with a delayed wound healing, oral aphthosis, edema,
pulmonary toxicity, bacterial infections, thrombocytopenia,
hyperlipidemia, and proteinuria [23].
In a recent randomized trial [21] involving 115 de novo
heart transplant recipients, an everolimus-based regimen
with early calcineurin withdrawal was associated with a sig-
nificant improvement in kidney function in comparison with
conventional CNI-based therapy.Whether everolimus initia-
tion and complete CNI withdrawal results in a better renal
outcome in maintenance cardiac transplant patients with
established renal dysfunction has not been investigated in
randomized trials. The present CECARI study (Certican
Initiation and Calcineurin Inhibitor Withdrawal in Mainte-
nance Heart Transplant Recipients with Renal Insufficiency)
was designed to assess this issue.
2. Materials and Methods
2.1. Study Design. CECARI was a three-year, prospec-
tive, multicenter, randomized, open-label trial, comparing
everolimus initiation and CNI withdrawal, with conven-
tional CNI-based therapy, in maintenance heart transplant
recipients with renal dysfunction. The study was conducted
between October 2007 and November 2013 at four transplant
centers in Belgium. The study protocol was approved by the
Institutional Review Board of each institution and conducted
in accordance with Good Clinical Practice and the Decla-
ration of Helsinki. All study participants provided written
informed consent. The study was registered at clinicaltrial-
sregister.eu (reference number 2007-002102-22). The study
design is shown in Figure 1.
2.2. Patients. To be eligible, patients had to be ≥18 years
old, have undergone heart transplantation ≥1 year pre-
viously, receive standard CNI-based immunosuppression,
and have moderate renal dysfunction (estimated GFR 30–
60mL/min/1.73m2). Patients with an identifiable cause of
chronic kidney disease other than CNI toxicity, treated acute
rejection in the previous 6months,malignancywithin the last
5 years, HIV, hepatitis B or C infection, current severe sys-
temic infection, current or planned pregnancy, severe throm-
bocytopenia (<75,000/𝜇L), leukopenia (<2500/𝜇L), anemia
(Hb < 8 g/dL), hypercholesterolemia (≥350mg/dL), hyper-
triglyceridemia (≥750mg/dL), or proteinuria (≥0.8 g/24 h)
were excluded.
2.3. Intervention. Patients were randomized in a 1 : 1 ratio
between (i) switch to everolimus plus mycophenolate mofetil
(MMF) with complete CNI withdrawal and (ii) continuation
of their previous treatment with CNI plus MMF. Steroid use
was left to the discretion of the treating physician, in both
groups. In the everolimus group, CNI dose was reduced by
50% and everolimus was initiated at 0.75mg twice daily. After
obtaining an everolimus trough level between 6 and 8 ng/mL,
CNI was discontinued. MMF was continued unchanged.
In the CNI group, baseline treatment with CNI (either
cyclosporine or tacrolimus) plusMMFwas continued. Target
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Figure 2: Study flowchart. CNI, calcineurin inhibitor; Cr-EDTA, measured glomerular filtration rate by Cr-EDTA clearance.
trough levels and dose adjustments were left to the discretion
of the treating physician.
2.4. Primary Endpoint, Efficacy, and Safety Assessment. The
primary endpoint was change in measured GFR (mGFR)
from baseline to year 3. The composite safety endpoint was
all-cause mortality, treated acute rejection episodes, or major
adverse cardiovascular events (MACE) at year 3. Secondary
endpoints were change in mGFR at year 1, the individual
subcomponents of the composite safety endpoint, proteinuria
and lipid profile, tolerability and occurrence of infection, and
other adverse events. mGFR was assessed by Cr-EDTA
clearance at baseline, year 1, and year 3.MACEwas defined by
cardiac death, acute myocardial infarction, need for coronary
revascularization, stroke, or admission for congestive heart
failure. Protocol myocardial biopsies were performed before,
one month and 12 months after CNI withdrawal in the
everolimus group, and additionally when clinically indicated.
Samples were evaluated locally according to the International
Society of Heart and Lung Transplantation (ISHLT) criteria
[33]. In the CNI group, myocardial biopsies were only
performed on indication.
2.5. Statistical Analysis. The primary endpoint, change in
mGFR from baseline to year 3, was compared between treat-
ment groups using an analysis of covariance (ANCOVA)with
the randomized group as a factor and the baseline value as
a covariate. Continuous variables were presented as mean ±
standard deviation or median and interquartile range (IQR),
as appropriate. Categorical variables were presented using
observed frequencies and percentages. Differences across
groups were assessed using the Wilcoxon rank-sum test for
continuous variables or the chi-square or Fisher’s exact test
for categorical variables, as appropriate. Time to event data
were assessed by Kaplan-Meier statistics and compared using
the log-rank test. For treated acute rejection and MACE,
cumulative incidence functions were used to estimate event
rates, whereby overall mortality was considered to be a com-
peting risk. Groups were compared using the Pepe-Mori test.
Efficacy analyses were conducted on all randomized patients
who had data available. A post hoc on-treatment analysis was
also conducted. A sample size of 50 patients (25 per treatment
arm) was estimated to have 80% power to detect a mean ±
SD difference between treatment groups of 8 ± 10mL/min.
Statistical significance for all analyses was set at a 2-tailed
probability level of 0.05. Statistics were performed with the
use of SAS software version 9.2 (SAS Institute Inc., Cary, NC)
for Windows.
3. Results
3.1. Patients. Fifty-nine patients were screened for participa-
tion. Two of them failed screening; thus, 57 patients were
randomized: 29 to the everolimus group and 28 to the CNI
group (Figure 2). Fifty-five completed the 1-year visit, and 51
completed the final 3-year visit; 6 patients died. No patients
were lost to follow-up, but Cr-EDTA clearance at year 3 could
not be obtained in 9 patients. Ten patients in the everolimus
group discontinued study drug and were switched back to
CNI (all during the first year); they were excluded in the post
hoc on-treatment analysis. Mean age at randomization was
59.7 years (SD = 13.3). Time after heart transplantation was
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Table 1: Baseline characteristics.
Everolimus (𝑁 = 29) CNI (𝑁 = 28) 𝑝 value
Age (years), mean ± SD 61.0 ± 14.9 58.3 ± 11.5 0.46
Female, 𝑛 (%) 2 (6.9) 1 (3.6) 1.0
Ethnic origin, Caucasian, 𝑛 (%) 29 (100) 28 (100) 1.0
Time posttransplant (years), median; IQR 7.6; 4.1–12.9 6.5; 3.7–12.1 0.82
Medical history, 𝑛 (%)
Hypertension 24 (82.8) 27 (96.4) 0.19
Diabetes mellitus 7 (24.1) 3 (10.7) 0.30
Laboratory values, mean ± SD
mGFR (mL/m) 38.5 ± 12.8 39.3 ± 11.2 0.38
Creatinine (mg/dL) 1.74 ± 0.28 1.66 ± 0.29 0.19
eGFR (mL/min/1.73m2) 41.6 ± 8.1 45.1 ± 7.6 0.09
Urea (mg/dL) 83.7 ± 28.2 74.1 ± 19.4 0.28
Total cholesterol (mg/dL) 161.2 ± 30.1 165.3 ± 43.0 0.95
Proteinuria (g/L) 0.12 ± 0.09 0.09 ± 0.07 0.20
Immunosuppression, 𝑛 (%)
Cyclosporine 19 (65.5) 20 (71.4) 0.63
Tacrolimus 10 (34.5) 8 (28.6) 0.63
MMF 29 (100) 28 (100) 1.0
Methylprednisolone 15 (51.7) 13 (46.4) 0.69
Concomitant medication, 𝑛 (%)
ACE-inhibitors 13 (44.8) 18 (64.3) 0.14
ARB 4 (13.8) 4 (14.3) 1.0
Loop diuretics 13 (44.8) 3 (10.7) 0.004
Spironolactone 3 (10.3) 0 0.24
Statins 29 (100) 28 (100) 1.0
SD, standard deviation; MMF, mycophenolate mofetil; ARB, angiotensin receptor blocker.
1 to 18 years (median 7.0, IQR 4.0–12.6). Demographics and
baseline characteristics did not differ significantly between
both groups (Table 1). Except for a higher proportion of
patients receiving loop diuretics in the everolimus group
(44.8% versus 10.7%, 𝑝 = 0.004), concomitant medication
was similar. All patients received statin therapy.
3.2. Immunosuppression. At baseline, patients in both groups
were treated with MMF and CNI, either cyclosporine (65.5%
in everolimus group, 71.4% in CNI group, 𝑝 = 0.63) or
tacrolimus. Forty-nine percent of patients were treated with
low dose methylprednisolone (51.7% in everolimus group,
46.4% in CNI group, 𝑝 = 0.69). Throughout the study, mean
everolimus trough levels were between 5.2 and 6.7 ng/mL,
which is a slightly lower than the intended 6–8 ng/mL. In
the CNI group, average cyclosporine and tacrolimus trough
levels were between 103 and 122 ng/mL and between 7.5 and
9.1 ng/mL, respectively.
3.3. Renal Function. At baseline, mean mGFR was similar in
both groups (38.5mL/min (SD = 12.8) in the everolimus
group and 39.3mL/min (SD = 11.2) in the CNI group,
𝑝 = 0.38). The change in mGFR did not differ significantly
between both groups after 1 year (+0.76mL/min (SD = 13.8)
in the everolimus group, −0.83mL/min (SD = 11.68) in the
CNI group, 𝑝 = 0.73). After 3 years, mGFR increased
by a mean of 7.0mL/min (SD = 14.9) in the everolimus
group and by 1.9mL/min (SD = 10.4) in the CNI group, but
the difference was not significant either (𝑝 = 0.18) (Fig-
ure 3). A post hoc analysis was performed to evaluate the
change in renal function after exclusion of the patients that
discontinued everolimus. In this on-treatment analysis, the
change in mGFR from baseline to year 3 did reach statistical
significance (+9.4mL/min (SD = 16.1) in the everolimus
group versus +1.9mL/min (SD = 10.4) in the CNI group,
𝑝 = 0.047).
3.4. Immunosuppressive Efficacy. There was no difference in
the composite endpoint of death, treated acute rejection or
MACE (31.0% versus 25.0%, 𝑝 = 0.50, Table 2). Individual
components of the composite safety endpoint were also
similar, except for a trend towards more treated rejection
episodes in the everolimus group (10.3% versus 3.6%, 𝑝 =
0.09). These rejections occurred early after switch from CNI
to everolimus: after 33 days, 68 days, and 371 days. None of
these rejections resulted in graft loss. There were 4 deaths
in the everolimus group (lung cancer, sudden cardiac death,
heart failure, and septic shock) and two in the CNI group
(lung cancer and sudden cardiac death) (𝑝 = 0.38).
3.5. Safety and Tolerability. There were significantly more
adverse events in the everolimus group (96.6 versus 57.1%,
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Table 2: Safety endpoints at year 3.
Everolimus (𝑁 = 29) CNI (𝑁 = 28) 𝑝 value
Composite endpoint, 𝑛 (%) 9 (31.0) 7 (25.0) 0.50
Death 4 (13.8) 2 (7.1) 0.38
Treated acute rejection 3 (10.3) 1 (3.6) 0.09
MACE 5 (17.2) 6 (21.4) 0.96
MACE, major adverse cardiovascular event; CNI, calcineurin inhibitor.
Table 3: Adverse events at year 3.
Everolimus (𝑁 = 29) CNI (𝑁 = 28) 𝑝 value
Any adverse event, 𝑛 (%) 28 (96.6) 16 (57.1) <0.001
Study drug discontinuation 10 (34.5) 0 <0.001
Infection 19 (65.5) 14 (50.0) 0.24
Infection with need for hospitalization 10 (34.5) 4 (14.3) 0.077
Neoplasm 2 (6.9) 3 (10.7) 0.67
Anemia 10 (34.5) 0 0.001
Leukopenia 6 (20.7) 1 (3.6) 0.10
Thrombocytopenia 1 (3.4) 0 1.0
Lower extremity edema 10 (34.5) 2 (7.1) 0.011
Skin rash 8 (27.6) 0 0.004
Oral aphtosis 5 (17.2) 0 0.052
Pulmonary toxicity 5 (17.2) 0 0.052
Diarrhea 7 (24.1) 2 (7.1) 0.14
CNI, calcineurin inhibitor.
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Figure 3: Mean (SEM) change in measured GFR from baseline.
CNI, calcineurin inhibitor; SEM, standard error of the mean.
𝑝 < 0.001, Table 3). The most common adverse events were
infection, anemia, lower extremity edema, and skin rash.
There was no significant difference in proteinuria (0.32 g/L
in the everolimus group versus 0.16 g/L in the CNI group,
𝑝 = 0.40) or total cholesterol (168.7 versus 174.0mg/dL,
𝑝 = 0.70). Malignancy occurred in 6.9% in the everolimus
group versus 10.7% in the CNI group (𝑝 = 0.67). Study drug
was discontinued in 10 patients (34.5%) of the everolimus
group due to adverse events. There were no study drug
discontinuations in the CNI group.
4. Discussion
The management of posttransplant renal dysfunction is
challenging.Thewidely recognized nephrotoxicity associated
with CNIs has prompted the search for everolimus-based
CNI-sparing and CNI-free regimens. However, after more
than a decade of experience with everolimus in heart trans-
plantation, the optimal strategy is still unknown.
The present CECARI study was the first to assess whether
an everolimus-based CNI-free strategy improves renal func-
tion in maintenance heart transplant recipients with estab-
lished renal insufficiency, compared with conventional CNI-
based therapy. The key findings of this small, prospective,
randomized,multicenter studywere as follows: (i) everolimus
initiation and CNI withdrawal in maintenance heart trans-
plant recipients did not lead to a significantly better renal out-
come; (ii) while feasible without loss of efficacy, adherence to
the everolimus regimen was relatively poor due to adverse
events; (iii) the selected patients that tolerated everolimus
(on-treatment analysis) did have a better renal outcome.
Everolimus has been investigated in de novo and main-
tenance heart transplant recipients before, as both part of a
CNI-sparing (dose reduction) and a CNI-free (complete CNI
withdrawal) strategy, with varying results on kidney func-
tion (Table 4). Eisen et al. [19] compared everolimus with
azathioprine, both in combination with standard exposure
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Table 4: Comparison of randomized trials of everolimus in heart transplant recipients.
𝑁 FU Timing∗ Intervention Control Renal function
Baseline Effect of intervention
(a) de novo
CNI-sparing
Eisen et al. [19] 634 1 y at Tx SE CsA + EVL SE CsA + AZA NA EVL worse
Lehmkuhl et al. [24] 176 1 y at Tx re CsA + EVL SE CsA + MMF eGFR 74.7 No significant difference
Eisen et al. [20] 721 1 y at Tx re CsA + EVL SE CsA + MMF eGFR 66.8 EVL worse
Zuckermann et al. [25] 199 6m at Tx re CsA+ EVL SE CsA + EVL SCr 1.3 No significant difference
Wang et al. [26] 25 6m at Tx re CsA + EVL SE CSA + EVL SCr 1.1 No significant difference
CNI-free
SCHEDULE [21, 27] 115 3 y +7w EVL + MMF SE CsA + MMF SCr 1.2 EVL better
MANDELA [28] 200 1 y +6m EVL + MMF re CNI + EVL NA Currently ongoing
(b) Maintenance
CNI-sparing
NOCTET [29, 30] 190† 5 y +6.3 y re CNI + EVL +MMF/AZA
SE CNI +
MMF/AZA mGFR 47.6 EVL better
SHIRAKISS [31] 34 3 y +2.6 y re CsA + EVL re CsA + MMF CrCl 43.9 No significant difference
Bara et al. [32] 70 1 y +4.8 y re CxA + EVL re CsA + MMF SCr 2.1 No significant difference
CNI-free
CECARI (present study) 57 3 y +7.0 y EVL + MMF re CNI + MMF mGFR 38.9 No significant difference
AZA, azathioprine; CNI, calcineurin inhibitor (cyclosporine or tacrolimus); CsA, cyclosporine A; EVL, everolimus; MMF, mycophenolate mofetil; re, reduced
exposure; SE, standard exposure; Tx, transplantation.
CrCl, creatinine clearance (mL/min); eGFR, estimated GFR (mL/min/1.73m2); mGFR, measured GFR (mL/min); NA, not available; SCr, serum creatinine
(mg/dL).
∗Timing of intervention relative to transplantation; FU, longest available follow-up; w, week; m, month; y, year.
†In NOCTET, a total of 282 patients were included: 190 heart transplant + 92 lung transplant recipients.
cyclosporine, in de novo heart transplantation. While show-
ing superior efficacy and benefit on CAV development,
everolimus was associated with a worse renal function; this
was attributed to the potentiation of cyclosporine nephrotox-
icity by everolimus. Lehmkuhl et al. [24] and Eisen et al. [20]
compared everolimus plus reduced exposure cyclosporine,
with standard exposure cyclosporine plus MMF. None of
these trials could show a renal benefit of the everolimus-
based CNI-sparing strategy. Zuckermann et al. [25] and
Wang et al. [26] investigated everolimus plus reduced expo-
sure cyclosporine versus everolimus plus standard exposure
cyclosporine but could not show a significant difference in
renal function, either. In contrast, a CNI-free regimen of
everolimus plus MMF did improve renal function in com-
parison with cyclosporine plus MMF in a trial of 115 de novo
heart transplant recipients in SCHEDULE [21].
Three randomized trials have investigated everolimus-
basedCNI-sparing strategies inmaintenance heart transplant
recipients. The SHIRAKISS [31] trial and the study of Bara et
al. [32] compared everolimuswithMMF, both in combination
with reduced exposure cyclosporine, but could not show a
better renal outcome of the everolimus strategy; there even
was a trend towards benefit of the MMF strategy. In contrast,
NOCTET [29], a randomized trial of 282 maintenance
thoracic transplant recipients (190 heart, 92 lung transplants),
comparing everolimus plus reduced exposure CNI plusMMF
with standard exposure CNI plus MMF, showed significant
improvement in renal function at one year in the everolimus-
group. The present study was the first randomized trial
investigating an everolimus-based CNI-free (instead of CNI-
sparing) regimen in maintenance heart transplant recipients.
Sirolimus, anothermTOR inhibitor, has been investigated in a
CNI-free regimen in maintenance heart transplant recipients
by Zuckermann et al. [34], showing improved renal function
compared with the CNI-group, but, analogous to our study, a
high discontinuation rate attributable to adverse events.
There are several possible explanations for the lack of
a significant renal benefit in the everolimus group in our
study. First, the median time after transplantation was long:
7.0 years. CNI elimination appears to be most effective in
the first years after heart transplantation [35, 36]; patients
with longstanding CNI exposure are less likely to benefit. In
NOCTET, the benefit of CNI reduction in maintenance
thoracic transplant patients was limited to those less than five
years after transplantation [37]. This probably reflects estab-
lished and irreversible renal damage. Second, the everolimus
discontinuation rate was high; this might have masked a
potential benefit of CNI withdrawal on renal function. The
on-treatment analysis suggests that patients who adhere
to the everolimus-based regimen do have a better renal
outcome. Third, although the two groups were relatively
well matched, there was a substantial difference in loop
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diuretic use: 44.8% in the everolimus group versus 10.7%
in the CNI group, 𝑝 = 0.004. This could have influ-
enced renal function in the everolimus group in a negative
way.
The current results indicate that everolimus initiation and
complete CNI withdrawal in maintenance heart transplant
recipients is feasible. The composite endpoint of all-course
mortality, MACE, and treated acute rejection was similar in
both groups. There was a trend towards a higher rate of
treated acute rejection, but this did not lead to graft loss.How-
ever, patients in the everolimus group had significantly more
adverse events. These mostly occurred during the first three
months and were most often benign and nonfatal (lower
extremity edema, oral aphthosis) but unfortunately led to a
high everolimus discontinuation rate.
The current study does not support a universal use
of everolimus for kidney protection in maintenance heart
transplant recipients. Rather, it suggests benefit in selected
patients. Other studies have found that patients at less than
five years after transplant [37] and those without baseline
proteinuria [31] are most likely to benefit. Future studies
should focus on these patients. Above all, they should try
to improve everolimus adherence. Most adverse events in
our trial occurred early after switching to everolimus. A
lower starting dose, followed by gradual everolimus up-
titration and concomitant CNI down-titration, might there-
fore improve tolerance. Finally, growing clinician’s experience
using everolimus and managing its adverse events could
potentially further reduce the discontinuation rate.
The present study had several limitations. First, the
number of study drug discontinuations was high. This may
have influenced the primary endpoint, as the on-treatment
analysis did show a significantly greater improvement in renal
function. Second, mean everolimus trough level was slightly
lower than the predefined target. However, this was not
associated with a loss of immunosuppressive efficacy. Third,
protocolmyocardial biopsies were performed at baseline, one
month, and one year in the everolimus group, whereas
biopsies were only performed on indication in theCNI group.
A detection bias for treated acute rejection episodes can
therefore not be excluded.
In conclusion, the present study did not show a signif-
icantly better renal outcome of everolimus initiation and
CNI withdrawal in maintenance heart transplant recipients.
However, poor adherence to the everolimus regimen meant
that the potential benefit of CNI withdrawal could not be
fully evaluated. Future protocols should considermeasures to
improve everolimus adherence.
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